Page 2 - Otol Neurotol News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Altamira Therapeutics Announces Publication of Positive Results from Phase 2 Trial with AM-125 in Acute Vestibular Syndrome in Leading Peer Reviewed Journal

Detailed results from TRAVERS trial addressing acute vestibular syndrome with AM-125 (intranasal betahistine) published in Otology & NeurotologyStudy demonstrates proof of concept and shows good tolerabilityTRAVERS

Thomas meyerOtol neurotolSecurities exchangeSecurities exchange commissionCompany nasdaqAltamira therapeuticsVestibular rehabilitation benefit questionnaireAltamira therapeuticSecurities actSecurities exchange actAltamira therapeutic annual reportAltamira therapeuticsview

Altamira Therapeutics (CYTO) Reports Publication of Positive Results from Phase 2 Trial with AM-125

Altamira Therapeutics (CYTO) Reports Publication of Positive Results from Phase 2 Trial with AM-125
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Thomas meyerOtol neurotolSecurities exchange commissionSecurities exchangeVestibular rehabilitation benefit questionnaireAltamira therapeuticSecurities actSecurities exchange actAltamira therapeutic annual reportAltamira therapeutics

Hearing loss in global spotlight as technology and research leaders collaborate to tackle rising impact, and experts unite to demystify care

/PRNewswire/ According to the World Health Organization (WHO), the number of people living with hearing loss is set to reach 2.5 billion by 2050.1 Now,.

United statesMeredith holcombSimon carlileBrent edwardsOtol neurotolLou ferrignoGoogle digital future initiativeMacquarie universityWorld health organizationAnalysis of health care deliveryUniversity of miami ear instituteCochlear limitedShepherd centreNational acoustic laboratoriesHearing implant programAustralian hearing hub members

FDA approves Cochlear s Nucleus 8 Sound Processor, smaller, smarter, better connected cochlear implant technology

/PRNewswire/ Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, receives U.S. Food and Drug Administration (FDA) approval for.

United statesGraeme clarkOtol neurotolBryan lopezLisa aubertInternational journalInternational journeyTechnology websiteDrug administrationCochlear limitedPrnewswire cochlear limitedBluetooth sig incHealth canadaMultichannel news releaseNucleus product managementConnected care

FDA approves Cochlear Nucleus Implants for unilateral hearing loss/single-sided deafness

/PRNewswire/ Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, obtained U.S. Food and Drug Administration (FDA) approval of.

United statesAnderson mlet alGraeme clarkKevin brownChristine menapaceOtol neurotolAudiol neurootolClinical affairsDrug administrationUniversity of north carolinaCochlear limitedPrnewswire cochlear limitedChildren cochlear implant centerVice presidentVice chairExecutive director